Indacaterol inhibits tumor cell invasiveness and MMP-9 expression by suppressing IKK/NF-κB activation

Area of Science:

• Pharmacology
• Cell Biology
• Respiratory Medicine

Background:

• The beta2 adrenergic receptor (ADRB2) is a key target for asthma and COPD treatments.
• Indacaterol is the only FDA-approved ultra-long-acting inhaled beta2-agonist (LABA) for COPD symptom relief.
• The exact molecular mechanism of indacaterol's therapeutic effect remains unclear.

Purpose of the Study:

• To elucidate the molecular mechanism of indacaterol's action in COPD.
• To investigate the role of beta-arrestin-2 in ADRB2 internalization upon indacaterol treatment.
• To determine indacaterol's effect on TNF-α/NF-κB signaling pathways and downstream effects.

Main Methods:

• Investigated beta-arrestin-2 mediated internalization of ADRB2 after indacaterol treatment.
• Assessed the impact of indacaterol on TNF-α-induced NF-κB activity, including IKK and IκBα phosphorylation.
• Evaluated indacaterol's effect on NF-κB target gene MMP-9 expression and cell migration/invasiveness.

Main Results:

• Beta-arrestin-2 mediates ADRB2 internalization following indacaterol administration.
• Indacaterol significantly inhibits TNF-α-induced NF-κB activity by reducing phosphorylated IKK and IκBα.
• Indacaterol decreases NF-κB nuclear translocation, MMP-9 expression, and TNF-α/NF-κB-induced cell invasiveness and migration.

Conclusions:

• Indacaterol's therapeutic effects in COPD may stem from a beta-arrestin-2-dependent inhibition of NF-κB activity.
• This mechanism potentially prevents further lung damage and improves lung function in COPD patients.
• Indacaterol demonstrates potential beyond bronchodilation by modulating inflammatory pathways.